Obizur (Susoctocog Alfa)

Susoctocog alfa, the active ingredient in Obizur, is a recombinant factor VIII (rFVIII) product presented as an intravenous solution for IV use. It treats hemophilia A by replacing deficient clotting factor VIII in patients with this inherited bleeding disorder. GNH USA supplies Obizur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Obizur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Obizur is a recombinant factor VIII product used in the management of hemophilia A, a disorder of the clotting cascade.

- On‑demand treatment of bleeding episodes: Provides rapid clotting factor replacement to stop active bleeding. - Peri‑operative management: Raises factor VIII levels before surgery or invasive procedures to reduce bleeding risk. - Routine prophylaxis: Regular infusions to maintain baseline factor VIII activity and prevent spontaneous bleeds. - Immune tolerance induction: Used in some protocols to reduce inhibitor development against factor VIII. - Post‑trauma replacement: Restores factor VIII after traumatic injury in hemophilia A patients.

Adverse reactions to Obizur are generally related to its protein nature and the intravenous route.

Common Side Effects: - Headache - Fever - Nausea - Injection site erythema - Mild arthralgia - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Development of inhibitors (neutralizing antibodies) to factor VIII - Anaphylactic or severe hypersensitivity reactions - Thromboembolic events - Severe hypertension - Renal impairment - Disseminated intravascular coagulation (DIC)

When using Obizur, clinicians should consider several safety and handling measures.

- Inhibitor monitoring: Test for factor VIII inhibitors before and during therapy. - Allergy assessment: Evaluate history of hypersensitivity to plasma‑derived or recombinant clotting factors. - Renal function: Monitor renal parameters in patients with pre‑existing kidney disease. - Cardiovascular status: Observe blood pressure and signs of thrombosis, especially in high‑risk patients. - Concomitant anticoagulants: Adjust dosing if the patient is receiving anticoagulant therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Obizur may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid): - Concurrent use of activated pro‑thrombin complex concentrates (aPCC) may increase thrombotic risk. - High‑dose bypassing agents combined with Obizur can precipitate uncontrolled clot formation.

Moderate Interactions (Monitor Closely): - Antifibrinolytics (e.g., tranexamic acid) may enhance clot stability; monitor for excessive clotting. - Immunosuppressants may alter inhibitor development; regular inhibitor screening is advised. - Certain antibiotics (e.g., beta‑lactams) have been associated with rare hypersensitivity when given with recombinant proteins. - Vaccines administered intramuscularly should be spaced to avoid overlapping immune activation.